Condition
Crohn's disease news across medications, symptoms, tests, procedures, complications, research, access, and daily life.
Page 13 of 53 · 2517 articles
Patients and clinicians often need evidence about whether switching from ustekinumab to an anti‑TNF (infliximab or adalimumab) still gives meaningful clinical responses. This study suggests many patients can respond, but...
Obese patients with FibroScan-detected steatosis in this cohort had a high frequency of colitis and some cases of IBD, dysplasia, and cancer, which could affect screening and symptom evaluation decisions.
Malnutrition was common in this group and linked to lower fistula healing and a higher chance of needing proctectomy or abdominal surgery — outcomes that matter to people with perianal Crohn’s disease.
Refractory IBD in children is linked to growth and development problems, hospitalizations, and surgery; knowing treatment options after anti‑TNF failure matters for long‑term outcomes. The review highlights which...
FDA IND clearance lets PALI‑2108 move into a Phase 2 trial in Crohn’s disease, meaning the drug’s safety and efficacy will be formally tested in people with moderate-to-severe disease. The program is being run alongside...
A pro athlete’s experience with perianal Crohn’s disease shows how chronic pain and major surgery can disrupt training and life, and offers practical strategies (advocacy, rehab, pacing) that other people with IBD may...
Cure8 found this source from marketscreener.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. Open the original article for...
Fatigue is extremely common in IBD and is closely linked to depression—recognizing and addressing mental-health issues may be important for patients who report significant fatigue.
Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and CRP. The original article is from Journal of medical biochemistry.
This study gives real-world 52‑week data on upadacitinib maintenance in children with refractory Crohn's disease, showing meaningful remission rates but also notable adverse events. That balance is important for families...
Orofacial granulomatosis often co-occurs with Crohn's disease and appears linked to a distinct Crohn's phenotype and treatment needs. The findings suggest that advanced therapies can be effective for OFG-associated CD...
FDA clearance lets Palisade start a Phase 2 trial of PALI-2108 in moderate-to-severe Crohn’s disease, which could matter to patients and clinicians watching new oral treatments targeted to the lower intestine.
Based on the title and source metadata, this appears to be an opinion or commentary related to Crohn's disease, Inflammatory bowel disease, and Biomarkers. The original article is from Digestive and liver disease :...
Distinguishing Crohn’s disease from intestinal tuberculosis is a frequent problem in TB-endemic areas; a validated mobile ML tool could help clinicians make more accurate, faster diagnostic decisions and avoid...
Cure8 indexed source-provided abstract text from The Laryngoscope, but this record did not meet the threshold for a full Cure8 brief. It is tagged for Crohn's disease and Complications.
Fibrotic strictures in Crohn’s disease often don’t respond to medication and may need endoscopic or surgical treatment. This trial directly compares two endoscopic options to see which is safer and more effective at...
Fibrotic strictures are a major cause of symptoms and surgery in Crohn’s disease; an oral anti‑fibrotic drug could offer a non‑surgical treatment option if trials show benefit and safety. This study tests RXC008...
Microbial amino-acid metabolites may be active players in IBD biology and could become useful biomarkers or therapeutic targets. Understanding these metabolites helps explain links between the microbiome, immune...
Strictures cause obstructive symptoms and repeat surgery in Crohn’s disease; endoscopic options can relieve obstruction and potentially avoid or postpone surgery for some patients.
If disease activity hurts quality of life partly through low self-efficacy and (for UC) psychological distress, then boosting self-management confidence and identifying anxiety/depression could help improve...
A blood biomarker that flags higher risk for complicated Crohn's could help identify people who may need closer monitoring or earlier treatment escalation before clear symptoms or endoscopic inflammation appear.
Patient engagement in treatment decisions can affect satisfaction, adherence, and care planning. This study identifies practical factors (treatment options, trusted providers, community support) associated with higher...
VEO-IBD often presents with severe, extensive disease and can include monogenic causes and early hepatobiliary complications; knowing common presentations and early management patterns helps families and clinicians plan...
People diagnosed as IBDU want to know whether their disease course, treatment needs, and chance of later being reclassified differ from typical UC or Crohn's disease.
The study compares ustekinumab effectiveness between biologic‑naïve and biologic‑experienced Crohn’s patients and links clinical response to better quality of life and reduced anxiety — information relevant when...
Predicting which children with Crohn disease will need surgery — and roughly when — could help families and clinicians plan treatments, monitoring, and discussions about elective bowel resection earlier in the disease...
A non-invasive MRI method that correlates with histology and endoscopic scores could reduce the need for frequent colonoscopy for assessing IBD activity and help monitor treatment response, especially when endoscopy is...
The study proposes a new immunomodulatory approach—phosphatidylserine liposomes—that reduced inflammation in mouse colitis models and altered monocyte and T-cell responses, which could point toward future therapies for...
Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Capsule Endoscopy. The original article is from BMC Gastroenterology.
If MSCs can limit ferroptosis via CBS, that points to a new biological pathway that might be targeted to reduce intestinal inflammation in Crohn's disease. This could guide future lab research and eventually early-phase...
The paper reframes Crohn’s disease and ulcerative colitis in terms of dominant T-helper immune pathways (TH1 vs TH22), which could steer research on targeted immunologic treatments and biomarkers.
Crohn’s disease prevalence and new diagnoses are rising rapidly in Korea, especially among people in their 20s and 30s; that affects demand for diagnosis, long-term care, and affordable treatment.
This meta-analysis pulls together early trial evidence that TL1A antagonists may improve clinical, endoscopic, and histologic outcomes in both UC and CD and reports an overall acceptable short-term safety...
The study suggests a mechanism (reduced intestinal oxalate transport) that could make common “healthy” plant foods aggravate intestinal inflammation in some people with Crohn’s or ulcerative colitis, which could affect...
Researchers planned to study whether patterns in the gut microbiome correlate with clinical diagnoses (including Crohn’s and UC), which could inform future biomarker work. The study is suspended, so no results are...
Understanding how patient-derived epithelial cells respond to inflammation could reveal mechanisms of poor mucosal healing in IBD and identify targets or biomarkers to improve repair. Organoid models from patient tissue...
A validated, disease-specific self-care scale could help measure and track self-management behaviors that affect daily life and clinical outcomes for people with IBD, and support research and clinical care focused on...
Cognitive symptoms like fluctuating attention can accompany Crohn’s disease and appear linked to clinical activity; recognizing these changes may help patients and clinicians monitor overall disease impact beyond gut...
Sarcopenia (loss of muscle mass) appears common in people with IBD and is linked to markers of active disease and anemia; identifying it could point to patients who need nutritional or rehabilitation support.
How patients think about their IBD affects coping, treatment adherence, and quality of life. If different generations perceive illness threat and control differently, clinicians and care teams may need to tailor...
Patients and clinicians using ustekinumab may be able to use an early (around 3 months) drug concentration to help predict short-term remission, while routine repeated monitoring later on may be less informative for...
The paper proposes molecular links between Crohn’s disease and Alzheimer’s disease through two genes implicated in inflammation and tissue remodeling. This could shape future research into shared gut–brain inflammatory...
Antibiotics can cause microbiome injury that increases risk of C. difficile and may worsen long-term health issues; identifying ways to protect the gut microbiome during antibiotic use could be especially relevant for...
The project investigates how TNFR1 and TNFR2 differently control epithelial repair in the colon—mechanisms that may explain why many patients on anti‑TNF biologics do not achieve lasting mucosal healing and could point...
Many people with IBD have ongoing IBS-like symptoms despite little or no intestinal inflammation. This project targets brain–gut and autonomic mechanisms that might explain symptom persistence and tests a non-drug...
This project describes a novel off-the-shelf engineered regulatory T cell therapy aiming to promote intestinal immune regulation and mucosal healing — a different approach than current biologics. If successful, it could...
The study tests whether common environmental chemicals (PFAS) could alter protein glycosylation and raise the later risk of IBD, which could point to preventable risk factors and early biomarkers.
The study identifies epithelial IFN‑I signaling as a driver of barrier failure in anti‑TNF refractory Crohn’s disease and suggests that blocking IFN‑I could be a rescue strategy for patients who do not respond to...
